Rheumatology (Oxford, England) · 2026
Psoriasis patients with psoriatic arthritis demonstrate a reduced regulatory capacity for neutrophil elastase.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Macleod Tom, Dubash Sayam R, Hyde Isabel, Michelena Xabier, Berekmeri Anna, Helliwell Philip S, Kingsbury Sarah R, Laws Philip, Mankia Kulveer, Stacey Martin, Marzo-Ortega Helena, Wittmann Miriam
Аннотация
OBJECTIVES: Identifying which patients with psoriasis (PsO) may develop PsA is a research priority. We have previously shown that elafin, along with IL-36γ, are excellent cutaneous biomarkers for PsO. The protease inhibitor elafin and its target protease, neutrophil elastase (NE), can be detected in both serum and epidermal samples. Our aims were to assess whether known PsO biomarkers are expressed differentially in patients affected by plaque PsO with and without PsA.
METHODS: Protein expression of NE and elafin were analysed in matched epidermal samples and serum of PsO, PsA patients and healthy controls. Findings were validated in independent PsA and arthritis cohorts.
RESULTS: The ratio between NE and elafin differed significantly between PsO and PsA patients. Expression of elafin was reduced in PsA samples as compared with plaque PsO patients. The ratio of NE to secretory leucocyte protease inhibitor was also increased in PsA as compared with PsO patients with no PsA, healthy controls and other arthritis patients.
CONCLUSIONS: PsA patients show a reduced NE inhibitor expression in both the skin and blood compartment compared with those with plaque PsO only. This may suggest differences in the ability to regulated neutrophil activity in PsA patients.
METHODS: Protein expression of NE and elafin were analysed in matched epidermal samples and serum of PsO, PsA patients and healthy controls. Findings were validated in independent PsA and arthritis cohorts.
RESULTS: The ratio between NE and elafin differed significantly between PsO and PsA patients. Expression of elafin was reduced in PsA samples as compared with plaque PsO patients. The ratio of NE to secretory leucocyte protease inhibitor was also increased in PsA as compared with PsO patients with no PsA, healthy controls and other arthritis patients.
CONCLUSIONS: PsA patients show a reduced NE inhibitor expression in both the skin and blood compartment compared with those with plaque PsO only. This may suggest differences in the ability to regulated neutrophil activity in PsA patients.